site map
contact
advanced search
home
news
treatment & care
hiv worldwide
living with hiv
preventing hiv
organisations
hiv basics
about us
Aidsmap
starting treatment news
Russian
Français
Português
Español
YOU ARE HERE:
> home
>
> Key topic guides
>>
> News categories
Starting treatment news
page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
of 15
next
Headline
Date
High rate of death amongst patients with HIV diagnosed late
20.11.08
IL-2 provides quick ‘AIDS rescue’, but effect does not always last
17.11.08
Treatment breaks set for a come-back?
12.11.08
Kivexa
downgraded to alternative status in revised US HIV treatment guidelines
05.11.08
Enhanced
Trofile
assay better at identifying HIV tropisms, only slight impact on virologic outcomes
31.10.08
Tenofovir/FTC more effective than abacavir/3TC in first-line boosted-PI regimens: meta-analysis
29.10.08
Start treatment at CD4 cell counts below 500, says large cohort study
27.10.08
No significant differences between elvucitabine and 3TC at 48 weeks
27.10.08
Raltegravir non-inferior to efavirenz: 48 week, phase III results
27.10.08
Once-daily darunavir (
Prezista
) approved for first-line use in United States
22.10.08
Is there a role for tropism testing in routine HIV care?
22.10.08
Low rate of spontaneous hepatitis C clearance in patients with HIV; early HIV treatment recommended for those with chronic hepatitis C infection
02.10.08
Hypersensitivity testing for abacavir slightly more cost-effective than tenofovir use, if both drugs equally potent
30.09.08
More evidence that antiretrovirals reduce the risk of non-HIV illnesses at lower CD4 cell counts
23.09.08
Patients staying on first-line HIV treatment combinations for longer
16.09.08
Study shows patients in their 30s at time of HIV infection have best response to HIV therapy
10.09.08
Poor results using non-medical HIV counsellors to screen for treatment eligibility in Malawi
03.09.08
How does abacavir/3TC compare to tenofovir/FTC? ACTG5202 and GSK studies disagree
08.08.08
Slowing CD4 cell decline with IL-2 allows HIV treatment to be deferred by 92 weeks
06.08.08
Efavirenz superior to lopinavir/ritonavir in very advanced HIV, Mexican trial shows
06.08.08
aidsmap links
Starting treatment
Alternative & complementary therapies
Choosing a combination
Choosing your treatment strategy
Discordant CD4 cell count and viral load responses
Drug diary
Immune restoration illnesses
Initial regimens in resource-limited settings
Late drug doses
No Nukes?
Primary infection
Prophylaxis and immune recovery
Resistance testing to select treatment
Starting treatment
UK trials for people new to treatment
UK trials for people new to treatment
When to start treatment
When to start treatment
subscribe to aidsmap email bulletins
page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
of 15
next
key topic guides
Key topic guides
News categories
Links categories
other news categories
latest news
Adherence news
Africa news
AIDS funding news
Asia and Pacific news
Basic science news
Changing treatments news
Children and HIV news
Circumcision news
Community involvement news
Conference news
Developed world news
Eastern Europe and Russia news
Gay men news
Hepatitis news
HIV and cancer news
HIV and drug use news
HIV and sexual health news
HIV and the law news
HSV-2
Latin America news
Lipodystrophy news
Medical tests news
Mental health news
Microbicides news
Middle East news
Mother-to-child transmission news
New drugs news
News Features
Palliative care news
Pharmacokinetics news
Prevention news
Resistance news
Salvage treatment news
Side-effects news
Starting treatment news
Statistics and epidemiology news
Treatment access news
Treatment interruptions news
Tuberculosis news
UK news
Vaccines news
Women and HIV news
World policy News
Support our work today